DNA Nanobots Deliver Cancer Drugs to Specific Cells

Cancer treatments often come with severe side effects. However, a major scientific breakthrough is changing how we approach the disease. Researchers are currently deploying microscopic DNA robots to safely target and destroy cancer cells. This highly precise method promises to deliver powerful drugs directly to tumors while sparing surrounding healthy tissue.

The Science of DNA Origami

To understand how a robot can be made from biological material, we have to look at a technique called DNA origami. Scientists at institutions like Arizona State University (ASU) and the Wyss Institute at Harvard University are not using DNA to pass down genetic traits. Instead, they use DNA as a structural building block.

DNA consists of four chemical bases (adenine, guanine, cytosine, and thymine) that naturally pair up in highly predictable ways. By taking a long single strand of DNA and mixing it with shorter “staple” strands, researchers can force the DNA to fold into specific three-dimensional shapes.

For cancer treatment, scientists design these structures to look like hollow tubes or tiny clamshells. These nanobots are incredibly small. A typical DNA nanobot measures roughly 90 by 60 nanometers. To put that in perspective, a single nanobot is thousands of times smaller than a human hair.

How DNA Nanobots Locate Cancer

Traditional chemotherapy floods the entire body with toxic chemicals. This approach kills cancer cells but also damages healthy cells in the stomach, hair follicles, and bone marrow. DNA nanobots solve this problem through a highly targeted delivery system.

The outside of the DNA nanobot is equipped with special targeting locks. These locks are made of custom-designed DNA sequences called aptamers. Aptamers function exactly like homing devices. They ignore healthy tissue and only react when they encounter a specific protein found on the surface of cancer cells.

In many recent studies, researchers programmed the aptamers to search for nucleolin. Nucleolin is a protein that is overproduced on the surface of tumor blood vessel cells but rarely found on the surface of healthy cells. When the nanobot bumps into a cell coated in nucleolin, the aptamer binds to the protein. This binding action triggers the nanobot to open up and release its hidden cargo directly into the tumor.

Delivering the Payload: Thrombin and Doxorubicin

The hollow center of the DNA nanobot carries the medicine. Researchers have successfully loaded these microscopic robots with different types of cancer-fighting agents.

One of the most successful payloads used by teams at the National Center for Nanoscience and Technology (NCNT) in Beijing is thrombin. Thrombin is a naturally occurring blood-clotting enzyme. When the nanobot attaches to the tumor blood vessel and opens up, it exposes the thrombin to the tumor’s blood supply.

This triggers a massive and localized blood clot. The clot acts as a physical roadblock, completely cutting off the blood flow to the tumor. Without a steady supply of oxygen and nutrients from the blood, the tumor tissue rapidly dies.

In other experiments, scientists have loaded the nanobots with doxorubicin, a standard chemotherapy drug. By hiding the toxic doxorubicin inside the closed DNA clamshell, the drug travels safely through the bloodstream without making the patient sick. It only deploys the medicine once the nanobot physically touches the target cancer cell.

Proven Success in Laboratory Models

The results of these targeted treatments in laboratory settings are highly encouraging. In a landmark 2018 study led by researcher Hao Yan at ASU, scientists injected DNA nanobots into mice with human breast cancer, melanoma, ovarian cancer, and lung cancer.

The results were incredibly fast. Within 24 hours of the injection, the nanobots had successfully located the tumors and blocked their blood supply. The researchers noted extensive tumor tissue death (necrosis) in the days following the treatment.

In the melanoma model, three out of eight mice showed complete regression of the tumors. Most importantly, the research team found no evidence that the nanobots caused blood clots in the healthy tissues of the mice. The nanobots also proved completely safe for the animals’ immune systems. Once the nanobots finished their job, the mice naturally degraded and cleared the DNA structures from their bodies within a few days.

Overcoming Obstacles for Human Trials

While the laboratory results are extremely promising, bringing DNA nanobots to local hospitals will take a few more years. Scientists are actively working to solve several manufacturing and biological challenges before clinical trials in humans can begin.

• Mass Production: Creating customized DNA structures in a small laboratory is manageable, but producing enough medical-grade nanobots for millions of human patients requires entirely new manufacturing processes.
• Immune System Evasion: A human immune system is much more complex than a mouse immune system. Researchers must ensure that human white blood cells do not mistake the DNA nanobots for invading viruses and destroy them before they reach the cancer.
• Target Accuracy: Tumors frequently mutate. Scientists are working to design nanobots with multiple types of aptamers so the robot can identify a tumor even if the cancer changes its surface proteins.

Biotechnology companies and university researchers are aggressively pursuing these solutions. The goal is to move DNA nanobots out of preclinical animal models and into Phase 1 human clinical trials within the next five to ten years.

Frequently Asked Questions

What is DNA origami? DNA origami is a nanoscale engineering technique. Scientists take long strands of DNA and use smaller chemical staples to fold the strands into specific 3D shapes. These shapes are used to build microscopic tools like drug-delivery nanobots.

Are DNA nanobots safe for the human body? Current research shows they are very safe. Because they are made from naturally occurring biological materials, the body can easily break them down and filter them out through the kidneys and liver once their job is done.

Will DNA nanobots replace traditional chemotherapy? Eventually, researchers hope they will. By carrying chemotherapy drugs directly to a tumor, nanobots could eliminate the severe side effects associated with modern cancer treatments like hair loss and severe nausea.

When will this treatment be available to the public? DNA nanobots are currently in the preclinical testing phase. Researchers need to complete mass manufacturing tests and secure FDA approval for human trials. It will likely be five to ten years before this technology is widely available in hospitals.